Company Profile

Medtronic is a global leader in medical technology, redefining how technology is used in the management of chronic disease. Our deep understanding of human physiology yields unique insight into a range of therapeutic areas, including heart and vascular diseases, diabetes, neurological disorders, and spinal conditions. This breadth of offerings, combined with our years of experience, allows us to deliver therapies that are transforming the treatment of chronic disease and changing the lives of more than 7 million patients worldwide each year.

Headquartered in Minneapolis, Minnesota, USA, Medtronic employs 45,000 people. The company operates regional headquarters in Switzerland and Singapore, and develops, manufactures and markets medical devices in more than 120 countries. Medtronic stock is traded on the New York Stock Exchange under the ticker symbol MDT.

Global Restructure

During the fourth quarter of fiscal year 2011 Medtronic initiated a global restructuring to reshape the business for long-term growth. The process, which involved scaling back in slower-growing areas of our business while continuing to invest in geographies, businesses and products where we anticipate faster growth, resulted in a 4 percent global workforce reduction affecting approximately 1,700 people. Medtronic offered voluntary separation and early retirement programs, which reduced the number of involuntary separations.

Acquisitions

Medtronic completed the following acquisitions during fiscal year 2011:

  • ATS Medical, Inc., which expands our product offerings and pipeline of surgical valves, repair products and surgical ablation technologies.
  • Osteotech, which makes orthopedic-focused biologic products that spur regenerative healing and enhances our position in the spine, orthopedic trauma and dental markets and creates new opportunities in areas such as joint reconstruction, foot and ankle, sports medicine and neurosurgery.
  • Ardian, which provides Medtronic entry into a quickly growing market for catheter-based treatments for hypertension.

For details of our financial performance, please read our 2011 annual report.

To learn more about our key businesses, Cardiac Rhythm Disease Management, CardioVascular, Physio-Control, Diabetes, Neuromodulation, Spinal and Biologics, and Surgicial Technologies, please visit our corporate web site.